Accuray Incorporated (ARAY)Healthcare | Medical Devices | Madison, United States | NasdaqGS
0.27 USD
+0.03
(12.847%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 0.26 -0.01 (-0.012%) ⇩ (July 13, 2026, 7:44 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:27 a.m. EDT
The investment case for Accuray is currently broken on both the immediate and long-term fronts. Fundamentally, the company is trapped in a death spiral: revenues are contracting by nearly 7.5%, profitability is nonexistent with negative operating margins, and the balance sheet is dangerously leveraged with debt-to-equity exceeding 400%. The multi-year price trajectory confirms this deterioration, showing a catastrophic 74% loss of value over the last nine years, with the stock failing to recover even during the brief periods of nominal growth. While the valuation metrics like P/S look cheap, they reflect a business that is actively shrinking and burning cash. Short-term, the outlook remains bleak. The stock is trading significantly below its 50-day and 200-day averages, confirming a downtrend that shows no signs of reversal. The statistical forecast models a slight further decline, though with low confidence, which aligns with the weak technical setup. There is no catalyst visible to spark a bounce. Long-term, the structural damage is severe. The company has missed earnings repeatedly and lowered guidance, eroding trust with investors. The lack of a sustainable competitive moat in the face of shrinking revenues suggests the core business model is under threat. With no dividend to provide income and a high risk of dilution or bankruptcy given the cash burn, this is a security to avoid entirely. |
| Model | MAE |
|---|---|
| MSTL_126 ✓ | 0.147274 |
| MSTL_97_126 | 0.158602 |
| AutoARIMA | 0.164139 |
| AutoTheta | 0.194980 |
| AutoETS | 0.209107 |
| MSTL | 0.220161 |
| MSTL_97 | 0.229676 |
Forecast horizon: 60 days | Selected: MSTL_126
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 2.05 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.176 |
| Excess Kurtosis | -1.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 437.329 |
| Revenue per Share | 3.641 |
| Market Cap | 32,393,816 |
| Forward P/E | -1.13 |
| Beta | 1.39 |
| Profit Margins | -10.76% |
| Website | https://www.accuray.com |
As of July 11, 2026, 5:27 a.m. EDT: Options activity reveals a distinct lack of bullish positioning. Call volume and open interest are negligible across all expirations, with zero in-the-money calls. Conversely, put activity is concentrated in the December expiration, where significant open interest exists at strikes far above the current price (2.0 vs 0.24), indicating deep out-of-the-money protection or a hedge against a potential recovery to par rather than a crash. The implied volatility is extremely low, suggesting the market has priced in a flat or dead outcome with minimal expectation of a sharp move either way.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8235294 |
| Address1 | 1,240 Deming Way |
| All Time High | 31.09 |
| All Time Low | 0.24 |
| Ask | 0.312 |
| Ask Size | 1 |
| Audit Risk | 10 |
| Average Analyst Rating | 3.0 - Hold |
| Average Daily Volume10 Day | 2,609,150 |
| Average Daily Volume3 Month | 3,434,044 |
| Average Volume | 3,434,044 |
| Average Volume10Days | 2,609,150 |
| Beta | 1.39 |
| Bid | 0.2352 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | 0.351 |
| City | Madison |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.2723 |
| Current Ratio | 1.424 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.2925 |
| Day Low | 0.2492 |
| Debt To Equity | 437.329 |
| Earnings Call Timestamp End | 1,778,099,400 |
| Earnings Call Timestamp Start | 1,778,099,400 |
| Earnings Timestamp | 1,778,097,600 |
| Earnings Timestamp End | 1,778,097,600 |
| Earnings Timestamp Start | 1,778,097,600 |
| Ebitda | -5,592,000 |
| Ebitda Margins | -0.013049999 |
| Enterprise To Ebitda | -31.603 |
| Enterprise To Revenue | 0.412 |
| Enterprise Value | 176,723,808 |
| Eps Forward | -0.24 |
| Eps Trailing Twelve Months | -0.38 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 608 824 2996 |
| Fifty Day Average | 0.3356 |
| Fifty Day Average Change | -0.063299984 |
| Fifty Day Average Change Percent | -0.18861736 |
| Fifty Two Week Change Percent | -82.35294 |
| Fifty Two Week High | 2.1 |
| Fifty Two Week High Change | -1.8276999 |
| Fifty Two Week High Change Percent | -0.8703333 |
| Fifty Two Week Low | 0.24 |
| Fifty Two Week Low Change | 0.03230001 |
| Fifty Two Week Low Change Percent | 0.13458338 |
| Fifty Two Week Range | 0.24 - 2.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,170,945,000,000 |
| Float Shares | 113,000,046 |
| Forward Eps | -0.24 |
| Forward P E | -1.1345834 |
| Free Cashflow | -10,882,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 990 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.26916 |
| Gross Profits | 115,356,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04354 |
| Held Percent Institutions | 0.69375 |
| Implied Shares Outstanding | 118,963,696 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ir Website | http://investors.accuray.com/phoenix.zhtml?c=177244&p=irol-irhome |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Long Business Summary | Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin. |
| Long Name | Accuray Incorporated |
| Market | us_market |
| Market Cap | 32,393,816 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_739115 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -46,130,000 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 28,670,250 |
| Number Of Analyst Opinions | 1 |
| Open | 0.25 |
| Operating Cashflow | -19,116,000 |
| Operating Margins | -0.024300002 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 29.49 |
| Phone | 608 824 2800 |
| Post Market Change | -0.0123000145 |
| Post Market Change Percent | -4.517082 |
| Post Market Price | 0.26 |
| Post Market Time | 1,783,986,254 |
| Previous Close | 0.2413 |
| Price Hint | 4 |
| Price To Book | 0.7757835 |
| Price To Sales Trailing12 Months | 0.07558565 |
| Profit Margins | -0.10764 |
| Quick Ratio | 0.576 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Region | US |
| Regular Market Change | 0.031 |
| Regular Market Change Percent | 12.8471 |
| Regular Market Day High | 0.2925 |
| Regular Market Day Low | 0.2492 |
| Regular Market Day Range | 0.2492 - 0.2925 |
| Regular Market Open | 0.25 |
| Regular Market Previous Close | 0.2413 |
| Regular Market Price | 0.2723 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 3,695,924 |
| Return On Assets | -0.01651 |
| Return On Equity | -1.01063 |
| Revenue Growth | -0.074 |
| Revenue Per Share | 3.641 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 118,963,696 |
| Shares Percent Shares Out | 0.040599998 |
| Shares Short | 4,828,854 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 8,093,447 |
| Short Name | Accuray Incorporated |
| Short Percent Of Float | 0.0466 |
| Short Ratio | 2.25 |
| Source Interval | 15 |
| State | WI |
| Symbol | ARAY |
| Target High Price | 0.35 |
| Target Low Price | 0.35 |
| Target Mean Price | 0.35 |
| Target Median Price | 0.35 |
| Total Cash | 38,067,000 |
| Total Cash Per Share | 0.32 |
| Total Debt | 182,396,992 |
| Total Revenue | 428,571,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.38 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.7629 |
| Two Hundred Day Average Change | -0.4906 |
| Two Hundred Day Average Change Percent | -0.6430725 |
| Type Disp | Equity |
| Volume | 3,695,924 |
| Website | https://www.accuray.com |
| Zip | 53,717-1954 |